• Which Patients With Flat Low-grade Dysplasia are at High Risk for Colorectal Cancer?

Which Patients With Flat Low-grade Dysplasia are at High Risk for Colorectal Cancer?

Detection of flat low-grade dysplasia (fLGD) and aneuploidy in colon tissues increases risk for high-grade dysplaisa (HGD) or colorectal cancer (CRC) more than 5-fold in patients with inflammatory bowel disease (IBD), researchers report in the December issue of Gastroenterology. Aneuploidy was also detected in almost all cases of flat HGD (fHGD) IBD is a risk

Read more
  • What is the Risk of Pancreatic Cancer in Patients with Low-Risk IPMNs?

What is the Risk of Pancreatic Cancer in Patients with Low-Risk IPMNs?

Low-risk intraductal papillary mucinous neoplasms have an almost 8% chance of progressing to pancreatic cancer within 10 years, whereas higher-risk IPMNs have almost 25% chance, reports a systematic review and meta-analysis in the October issue of Clinical Gastroenterology and Hepatology. Continued long-term surveillance is therefore important for patients with low-risk, as

Read more
  • How Does Transforming Growth Factor beta Suppress Colorectal Tumor Development?

How Does Transforming Growth Factor beta Suppress Colorectal Tumor Development?

Researchers review the mechanisms by which loss of transforming growth factor beta (TGFB) proteins contribute to development and progression of colorectal cancer in the January 2017 issue of Gastroenterology. Development and progression of colorectal cancer involve loss of tumor suppressor proteins, including transforming growth factor beta (TGFB) family members. In colon

Read more
  • What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

What is the Best Way to Predict Disease Progression in Patients With Inactive HBV?

In patients with chronic hepatitis B virus (HBV) infection who are negative for HBe antigen (HBeAg), monitoring levels of HB surface antigen (HBsAg) can predict disease progression, researchers report in the October issue of Clinical Gastroenterology and Hepatology. Most persons chronically infected with HBV clear HBeAg and enter an inactive carrier phase, characterized by low or undetectable

Read more
  • A Mouse Model for Studying Pancreatic Tumor Resection and Adjuvant Therapy

A Mouse Model for Studying Pancreatic Tumor Resection and Adjuvant Therapy

Researchers have developed mice that develop focal, resectable pancreatic tumors closely resembling human pancreatic ductal adenocarcinomas (PDACs) that can be used to test adjuvant therapies, according to new research in the August issue of Gastroenterology. The authors show that administration of gemcitabine after resection of the tumors activates natural killer (NK) cell-mediated

Read more
  • Does a PNPLA3 Polymorphism Promote Fibrosis Progression in Patients with Hepatitis C?

Does a PNPLA3 Polymorphism Promote Fibrosis Progression in Patients with Hepatitis C?

A single nucleotide polymorphism (SNP) in the patatin-like phospholipase domain containing 3 gene (PNPLA3) is associated with baseline level of fibrosis and its progression, but not development of hepatocellular carcinoma (HCC), in patients with hepatitis C virus (HCV) infection, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Most

Read more
  • A Nanoparticle-based Approach to Selectively Target Hepatocellular Carcinomas

A Nanoparticle-based Approach to Selectively Target Hepatocellular Carcinomas

Researchers have created nanoparticles that selectively kill hepatoma cells and reduce growth of liver tumors in rats, they report in the February issue of Gastroenterology. They show that the particles induce tumor-specific necrosis by selectively disrupting redox balance within cancer cells. Dietary intake of the natural omega-3 fatty acid docosahexaenoic

Read more
  • Does FibroScan Accurately Assess Liver Fibrosis?

Does FibroScan Accurately Assess Liver Fibrosis?

Vibration-controlled transient elastography (VCTE) with FibroScan can provide an accurate assessment of liver fibrosis in patients with chronic viral hepatitis, but operator-related and patient-related factors affect measurements, report 2 articles published in the April issue of Clinical Gastroenterology and Hepatology. The lowest levels of variation occur in patients with no

Read more
  • What to do About Sessile Serrated Adenomas

What to do About Sessile Serrated Adenomas

Sessile serrated adenomas (SSAs), characterized by the saw-toothed appearance of the colonic crypts, form and progress to colorectal cancers (CRCs) via a different pathway than conventional adenomas and are thought to contribute to 20% to 35% of all cases of CRC. Although little is known about their pathogenesis, endoscopists must be aware of the unique features of SSAs to efficiently detect

Read more

In Treating Crohn’s Disease, Earlier is Better

Patients receiving medical therapies when they have more complicated stages of Crohn’s disease (CD) are more likely to require surgery, researchers report in the March issue of Clinical Gastroenterology and Hepatology. The disease is most-effectively treated by drugs at its early, inflammatory stages. Patients have a 40%–71% risk for requiring

Read more